Please ensure Javascript is enabled for purposes of website accessibility Agustin Mohedas, PhD - Janus Henderson Investors
For financial professionals in Norway

Agustin Mohedas, Ph.D.

Portfolio Manager | Research Analyst

Agustin Mohedas is a Portfolio Manager and Research Analyst on the Health Care Team at Janus Henderson Investors. He is focused primarily on the biotechnology sector. Before joining the firm as a research analyst in 2019, Agustin was a senior analyst at Eventide Asset Management, working on the Healthcare and Life Sciences Fund from 2017. Prior to this, he was an analyst with RA Capital Management, a long/short hedge fund focused on biotechnology, from 2014.

Agustin received his bachelor of science degree in biomedical engineering from Texas A&M University, graduating summa cum laude. He also earned a PhD in medical engineering and medical physics from the Harvard-MIT Program in Health Sciences and Technology. His PhD research focused on drug development for a rare genetic disease, resulting in multiple patents and publications. He has 10 years of financial industry experience.

Articles Written

JH Explorer in Singapore: Tackling the obesity epidemic
Timely & Topical

JH Explorer in Singapore: Tackling the obesity epidemic

Agustin Mohedas discusses the market opportunity associated with GLP-1 agonists, the new drug tackling obesity.

I&I therapies hit new milestones for patients and investors
Timely & Topical

I&I therapies hit new milestones for patients and investors

The stocks of inflammation and immunology (I&I) focused companies have outperformed in 2023 and could continue to deliver in the years ahead.

Keeping perspective on AI’s role in biotech
Timely & Topical

Keeping perspective on AI’s role in biotech

While technology is an important aspect of drug discovery, the value of new medicines – and the firms developing them – comes down to the quality of clinical data.

Biopharma’s targeted approach to growth

Biopharma’s targeted approach to growth

A new drug targeting a common mutation found in tumors represents a breakthrough in cancer therapy and a potential new source of growth for biopharma.